Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population

References

• WHO (World Health Organization). Hepatitis C fact sheet. Geneva, Switzerland: World Health Organization, 2016. http://www.who.int/mediacentre/factsheets/fs164/en/ [Online, August 2, 2016].
   Google Scholar
• Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
   PubMedGoogle Scholar
• Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9:34
   PubMed Web of Science ®Google Scholar
• Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:268-76
   PubMed Web of Science ®Google Scholar
• Soriano V, Labarga P, Fernandez-Montero JV, et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antiviral Res 2013;97:36-40
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies and challenges. Gastroenterology 2014;146:1176-92
   PubMed Web of Science ®Google Scholar
• Bourlière M, Khaloun A, Wartelle-Bladou C, et al. Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterol 2011;35:S84-S95
   Google Scholar
• Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014;348:g3308
   PubMedGoogle Scholar
• Bourlière M, Bronowicki JP, Hezode CH, et al. Traitement des hépatites virales C Avis d’experts – mars 2014. Paris, France: Association reconnue d?utilite publique (AFEF), 2014. http://www.afef.asso.fr/ckfinder/userfiles/files/actualites/veille/Avisexperts-AFEF-Mars-2014.pdf. [December 18, 2015].
   Google Scholar
• Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med 2009;360:1902-6
   PubMed Web of Science ®Google Scholar
• Voelker R. Birth cohort screening may help find hepatitis C cases. JAMA 2012;307:1242
   PubMed Web of Science ®Google Scholar
• Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010;17:435-43
   PubMed Web of Science ®Google Scholar
• Brouard C, Le Strat Y, Larsen C, et al. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One 2015;10:e0126920
   PubMed Web of Science ®Google Scholar
• MASS (Ministère des Affaires Sociales et de la Santé). Prise en Charge des Personnes Infectées par les Virus de l'Hépatite B ou de l'Hépatite C: Rapport de Recommandations 2014. Paris, France: MASSe, 2014. http://social-sante.gouv.fr/IMG/pdf/Rapport_Prise_en_charge_Hepatites_2014.pdf [Online, February 9, 2015].
   Google Scholar
• Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int 2013;33(1 Suppl):68-79
   PubMed Web of Science ®Google Scholar
• InVS (Institut National de Veille Sanitaire). Prévalence des hépatites B et C en France en 2004. Saint-Maurice cedex, France: InVS, 2004.
   Google Scholar
• Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging Baby Boomers. Curr Gastroenterol Reps 2010;12:1-6
   PubMedGoogle Scholar
• Horne PM, Mills R. Implications of the 2012 Centers for Disease Control and Prevention (CDC) guidelines for screening hepatitis C infection in the United States. Pract Gastroenterol 2013;XXXVII:36-41
   Google Scholar
• INED (Institut National dÉtudes Démographiques). Population totale. Paris, France: INED, 2014. http://www.ined.fr/fr/publications/population/population-2014-n-3/. [Online, May 16, 2014]
   Google Scholar
• Rotily M, Vainchtock A, Jouaneton B, et al. How did chronic hepatitis C impact costs related to hospital health care in France in 2009? Clin Res Hepatol Gastroenterol 2013;37:365-72
   PubMed Web of Science ®Google Scholar
• InVS (Institut National de Veille Sanitaire). Surveillance nationale de l’hépatite C à partir des pôles de référence. Saint-Maurice cedex, France: InVS, 2007.
   Google Scholar
• Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Exp Hepatol 2016;2:34-7
   Web of Science ®Google Scholar
• Walker DR, Pedrosa MC, Manthena SR. Early view of the effectiveness of new direct-acting antiviral (DAA) regimens in patients with hepatitis C virus (HCV). Adv Ther 2015;32:1117-27
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Thein H-H, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31
   PubMed Web of Science ®Google Scholar
• Liu S, Cipriano LE, Holodniy M, et al. New protease inhibitors for the treatment of chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2012;156:279-90
   PubMed Web of Science ®Google Scholar
• Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010;32:344-55
   PubMed Web of Science ®Google Scholar
• Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-70
   PubMed Web of Science ®Google Scholar
• Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-8, 288 e1
   PubMed Web of Science ®Google Scholar
• Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States 1999-2008. Am J Transplant 2010;10:1003-19
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005;21:55-65
   PubMed Web of Science ®Google Scholar
• HAS, Haute Autorité de Santé. Choices in methods for economic evaluation. Haute Autorité de Santé, Department of Economics and Public Health Assessment. Saint Denis La Plaine Cedex, France: HAS, 2012.
   Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-92
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naïve patients? A cost-effectiveness analysis (ANRS N°95141). J Hepatol 2014;61:7-14
   PubMed Web of Science ®Google Scholar
• Assurance Maladie. Price of drugs in France. Paris cedex, France: Assurance Maladie, 2015.
   Google Scholar
• Schwarzinger M, Deuffic-Burban S, Mallet V, et al. Lifetime costs attributable to chronic hepatitis C from the French health care perspective (ANRS N°12188). J Hepatol 2013;58:S21-S2
   Web of Science ®Google Scholar
• HAS (Haute Autorité de Santé). Sovaldi (sofosbuvir), antiviral à action directe. Saint Denis La Plaine Cedex, France: HAS, 2014.
   Google Scholar
• Deuffic-Burban S, Obach D, Canva V, et al. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Viral Hepat 2016; doi:10.1111/jvh.12546 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cohen J. Infectious disease. Calling all baby boomers: get your hepatitis C test. Science 2012;337:903
   PubMed Web of Science ®Google Scholar
• Roehr B. Screen all baby boomers for hepatitis C, advises US public health agency. BMJ 2012;344:e3707
   Google Scholar
• Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care setting. Ann Intern Med 2012;156:263-70
   PubMed Web of Science ®Google Scholar
• Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep 2014;16:381
   PubMedGoogle Scholar
• Tramarin A, Gennaro N, Compostella FA, et al. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des 2008;14:1655-60
   PubMed Web of Science ®Google Scholar
• Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009;19:245-53
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014;60:832-43
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimen on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014;60:530-7
   PubMed Web of Science ®Google Scholar
• Hagan LM, Yang Z, Ehteshami M, et al. All-oral, interferon-free treatment or chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013;20:847-57
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Deltenre P, Louvet A, et al. Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France. J Hepatol 2008;49:175-83
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Mathurin P, Rosa I, et al. Impact of emerging hepatitis C virus on future needs for liver transplantation in France: a modelling approach. Dig Liver Dis 2014;46:157-63
   PubMedGoogle Scholar
• Papatheodoridis GV, Tsochatzis E, Hardtke S, et al. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int 2014;34:1452-63
   PubMed Web of Science ®Google Scholar